Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Iovance Biotherapeutics Raises 2026 Revenue Guidance

Iovance Biotherapeutics Raises 2026 Revenue Guidance

MT newswireMT newswire2026/09/29 11:21
07:21 AM EDT, 09/29/2026 (MT Newswires) -- Iovance Biotherapeutics (IOVA) said Tuesday it raised its full year 2026 total revenue guidance to a range of $410 million to $420 million, from prior outlook of $350 million to $370 million. Analysts polled by FactSet expect $402.8 million. Iovance said the outlook raise is driven by strong US demand for Amtagvi and Proleukin. Shares of the company were up more than 5% pre-bell Tuesday.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Only twice in history! S&P 500 equal-weight index is expected to record seven consecutive weeks of decline this week

The S&P 500 Equal Weight Index is expected to fall for a seventh consecutive week. If this downward trend continues through Friday, it will mark only the third time in history that the index has experienced seven straight weeks of decline.

智通财经•2026/09/30 23:17

Trump “bites” Powell, demanding his resignation from the Federal Reserve Board, citing severe cost overruns in headquarters renovation.

U.S. President Trump on Wednesday called for former Federal Reserve Chairman Powell to resign from his position as a Fed governor, following an inspector general report on the Federal Reserve headquarters renovation project, which highlighted a series of management issues that led to significant cost overruns.

智通财经•2026/09/30 23:17